Great news for Tempus AI stock! The company has just received FDA approval for an upgraded version of its Tempus Pixel platform — a cardiac imaging system that uses advanced AI to deliver highly ...

Tempus AI, Inc. is projected to achieve 30% YoY top line growth in Q4 2024 as presented in management's preliminary results. Growth is forecast to continue in the 23-25% range in eFY25. Tempus is ...

Revenue of approximately ~$367 million, an increase of approximately 83% year-over-year Diagnostics revenue of ~$266 million, representing ~121% growth year-over-year, driven by Oncology volume growth ...

Tempus AI hopes to leverage artificial intelligence and its massive data set to improve outcomes for patients. It has partnered with nearly all of the top oncology companies. The company grew its ...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the 43rd Annual J.P. Morgan ...

Revenue of approximately $200 million, an increase of approximately 35% year-over-year Continued trend of sequential improvement in adjusted EBITDA in the fourth quarter of 2024 “We concluded 2024 ...